Updated just now · Live
Stock analysis, price data, and AI-powered insights for Nkarta Inc (NKTX).
Nkarta Inc operates in the Biotechnology sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for NKTX.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). NKTX Stock Intelligence Report. [stoxpulse.com/stocks/nktx]
Disclaimer: The information on this page about Nkarta Inc (NKTX) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Nkarta Inc.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No price data available.
No earnings data available.
Nkarta shares are trading higher after the company...
5d ago
Nkarta announces FDA agreement on outpatient dosin...
6d ago
StoxPulse AI results for NKTX: Pulse Score 55/100. Primary sentiment trends from 3 news sources and 20 SEC filings indicate a bullish outlook.
Market Cap
$248.8M
P/E Ratio
—
EPS
$-0.29
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Nkarta shares are trading higher after the company announced an agreement with the FDA on protocols for its Ntrust-1 and Ntrust-2 clinical trials.
Nkarta announces FDA agreement on outpatient dosing of NKX019 in autoimmune disease, expanding access to community rheumatology centers
Nkarta Reveals FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease; Option To Redose Patients Granted In Both Ntrust-1 And Ntrust-2 Studies; Rheumatoid Arthritis Cohort To Be Added To Ntrust-2